Immunotherapy could be an alternative in this situation of high risk of relapse due to residual disease and ABMT-related immunodepression. The induction of LAK activity did not significantly differ from early and late IL2 treatments.
Clinical results are still inconclusive due to the small number of patients.
Sixteen patients were treated at 3 dose levels. Thirteen additional patients then were treated at 1 level below the MTD to try and decrease the interval between courses. The most common DLT was gastrointestinal toxicity followed by hematologic toxicity. Twenty-seven patients developed standard National Cancer Institute criteria Grade 3 or 4 toxicity after the first course of treatment and 7 patients achieved a complete or partial response to the first course. The use of GM-CSF did not allow further dose intensification.